News | Contrast Media | November 27, 2018

Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Study results demonstrate potential for creating equivalent of full-dose, contrast-enhanced MR images without any contrast agent use

Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

November 27, 2018 — Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in the body after magnetic resonance imaging (MRI) exams, according to a new study. The study was presented at the 2018 annual meeting of the Radiological Society of North America (RSNA), Nov. 25-30 in Chicago.

Gadolinium is a heavy metal used in contrast material that enhances images on MRI. Recent studies have found that trace amounts of the metal remain in the bodies of people who have undergone exams with certain types of gadolinium. The effects of this deposition are not known, but radiologists are working proactively to optimize patient safety while preserving the important information that gadolinium-enhanced MRI scans provide.

“There is concrete evidence that gadolinium deposits in the brain and body,” said study lead author Enhao Gong, Ph.D., researcher at Stanford University in Stanford, Calif. “While the implications of this are unclear, mitigating potential patient risks while maximizing the clinical value of the MRI exams is imperative.”

Gong and colleagues at Stanford have been studying deep learning as a way to achieve this goal. Deep learning is a sophisticated artificial intelligence technique that teaches computers by examples. Through use of models called convolutional neural networks, the computer can not only recognize images but also find subtle distinctions among the imaging data that a human observer might not be capable of discerning.

To train the deep learning algorithm, the researchers used MR images from 200 patients who had received contrast-enhanced MRI exams for a variety of indications. They collected three sets of images for each patient:

  • Pre-contrast scans, done prior to contrast administration and referred to as the zero-dose scans;
  • Low-dose scans, acquired after 10 percent of the standard gadolinium dose administration; and
  • Full-dose scans, acquired after 100 percent dose administration.

The algorithm learned to approximate the full-dose scans from the zero-dose and low-dose images. Neuroradiologists then evaluated the images for contrast enhancement and overall quality.

Results showed that the image quality was not significantly different between the low-dose, algorithm-enhanced MR images and the full-dose, contrast-enhanced MR images. The initial results also demonstrated the potential for creating the equivalent of full-dose, contrast-enhanced MR images without any contrast agent use.

These findings suggest the method’s potential for dramatically reducing gadolinium dose without sacrificing diagnostic quality, according to Gong.

“Low-dose gadolinium images yield significant untapped clinically useful information that is accessible now by using deep learning and AI,” he said.

Now that the researchers have shown that the method is technically possible, they want to study it further in the clinical setting, where Gong believes it will ultimately find a home.

Future research will include evaluation of the algorithm across a broader range of MRI scanners and with different types of contrast agents.

“We’re not trying to replace existing imaging technology,” Gong said. “We’re trying to improve it and generate more value from the existing information while looking out for the safety of our patients.”

Gong received an RSNA “Trainee Research Prize – Resident” award for his research.

For more information: www.rsna.org

Related Gadolinium Content

The Debate Over Gadolinium MRI Contrast Toxicity

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body?

VIDEO: Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

Related Content

Screening Mammography Could Benefit Men at High Risk of Breast Cancer
News | Mammography | September 18, 2019
Selective mammography screening can provide potentially lifesaving early detection of breast cancer in men who are at...
Radiation After Immunotherapy Improves Progression-free Survival for Some Metastatic Lung Cancer Patients
News | Lung Cancer | September 18, 2019
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates...
The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology

The Artis icono biplane angiography system is designed for use in neurointerventions and interventional radiology. Image courtesy of Siemens Healthineers.

Technology | Angiography | September 17, 2019
The U.S. Food and Drug Administration (FDA) has cleared the Artis icono, a high-precision family of angiography systems...
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Radiation Therapy | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of...
Varian Unveils Ethos Solution for Adaptive Radiation Therapy
News | Image Guided Radiation Therapy (IGRT) | September 16, 2019
At the 2019 American Society for Radiation Oncology (ASTRO) annual meeting, being held Sept. 15-18 in Chicago, Varian...
Long-term Hormone Therapy Increases Mortality Risk for Low-PSA Men After Prostate Surgery
News | Prostate Cancer | September 16, 2019
Secondary analysis of a recent clinical trial that changed the standard of care for men with recurring prostate cancer...
3D Systems Earns Additional FDA Clearance for D2P Medical 3-D Printing Software

3D Systems’ D2P FDA-cleared software allows clinicians to 3-D-print diagnostic patient-specific anatomic models. Image courtesy of 3D Systems.

Technology | Medical 3-D Printing | September 12, 2019
3D Systems has received additional U.S. Food and Drug Administration (FDA) 510(k) clearance for its D2P software...
FDA Clears GE Healthcare's Critical Care Suite Chest X-ray AI
Technology | X-Ray | September 12, 2019
GE Healthcare announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of Critical Care Suite, a...
Richardson Healthcare Receives CE Mark Approval for ALTA750 Canon/Toshiba CT Replacement Tube
News | Computed Tomography (CT) | September 11, 2019
Richardson Healthcare, a Division of Richardson Electronics Ltd., announced it has received CE Mark approval for the...
Bayer Introduces Medrad Stellant Flex CT Injection System
Technology | Contrast Media Injectors | September 11, 2019
Bayer announced the introduction of the Medrad Stellant Flex computed tomography (CT) injection system. Stellant Flex...